New sacral neuromodulation device gains equal Medicare payment under proposed CMS rule

CMS proposed granting the Neuspera Integrated Sacral Neuromodulation System the same Medicare payment rate as legacy implantable SNM devices in the 2027 payment rule. The decision, if finalized, would establish consistent reimbursement for the newer integrated system, potentially expanding treatment options for patients with overactive bladder and urinary retention. Providers offering urologic or pelvic floor services should review the proposed rule's details on CPT code alignment and payment specifics for this technology. The final rule is expected in November 2026.